Table III.

Patient-reported outcomes for palmoplantar psoriasis patients compared to plaque psoriasis patients.

	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	Adjusted P-value	Adjusted P- value for Multiple Comparisons a
DLQI score 6-30 (Moderate-Extremely Large impact on HRQoL)	2.18 (1.32-3.60)	2.08 (1.20-3.61) b	0.009	0.036
EQ-5D index score > median	0.68 (0.41-1.14)	0.88 (0.51-1.51) c	0.63	0.63
Problems with Mobility (EQ-5D)	1.89 (1.10-3.24)	1.98 (1.10-3.58) d	0.023
Problems with Self- Care (EQ-5D)	2.69 (1.23-5.92)	3.12 (1.24-7.86) e	0.016
Problems with Usual Activities (EQ-5D)	2.95 (1.75-4.98)	2.47 (1.44-4.22) f	0.001
Heavy prescription topical use in the last week g	3.37 (1.98-5.74)	2.81 (1.63-4.85) h	0.0002	0.001

Significant values with P < 0.05 are shown in bold.

^aAdjusted for multiple comparisons using the Holm-Bonferroni procedure.

^bAdjusted for age, sex, ethnicity, site, number of co-morbidities, psoriasis duration, and psoriasis severity at its worst.

^cAdjusted for age, sex, number of co-morbidities, smoking status, and marital status.

^dAdjusted for age, sex, marital status, number of co-morbidities, smoking status, and psoriasis severity at its worst.

^eAdjusted for age, sex, number of co-morbidities, psoriasis severity at its worst, and age of psoriasis onset.

^fAdjusted for age, sex, smoking status, number of co-morbidities.

^gDaily use with at least two applications per day.

^hAdjusted for age, sex, and type of therapy.